Optorhythm

Company Overview

Snapshot

Founded in August 2024 by Yaki Eidelstein, Optorhythm operates with 1–10 employees. The company is developing a novel light-based method for controlling heart rhythms, building on over two decades of research. In September 2024, Optorhythm secured Pre-Seed funding from NGT HealthCare II.

Business overview

Optorhythm is a Health Tech & Life Sciences company focused on developing an optogenetic therapy for Atrial Fibrillation (AF). The company's core technology integrates optogenetic gene therapy with an implantable micro-LED array to create an "Optic Defibrillator." This device is designed to stop chaotic atrial contractions through targeted light pulses, offering a real-time, repeatable, and non-destructive alternative to traditional electric shocks. Optorhythm aims to improve treatment for AF by providing sustained rhythm control and enhanced patient outcomes within the medical devices and medical treatment & therapeutics sectors, primarily serving healthcare providers.

Company Intelligence Q&A

What is Optorhythm's primary focus?

Optorhythm is developing an optogenetic therapy for the treatment of Atrial Fibrillation (AF) using an implantable optic device.

Who founded Optorhythm?

Optorhythm was founded by Yaki Eidelstein in August 2024.

What is the core technology behind Optorhythm's solution?

The company's technology integrates optogenetic gene therapy with an implantable micro-LED array to create an "Optic Defibrillator" designed to control heart rhythms with targeted light pulses.

Which investor participated in Optorhythm's Pre-Seed funding round?

In September 2024, Optorhythm received Pre-Seed funding from NGT HealthCare II.

What problem does Optorhythm aim to solve in cardiac care?

Optorhythm aims to address limitations in existing Atrial Fibrillation treatments by offering a non-destructive, repeatable method for sustained rhythm control, providing an alternative to traditional electric shocks.